JP2024520395A - 置換される縮合二環式大環状化合物および関連のある治療方法 - Google Patents

置換される縮合二環式大環状化合物および関連のある治療方法 Download PDF

Info

Publication number
JP2024520395A
JP2024520395A JP2023572622A JP2023572622A JP2024520395A JP 2024520395 A JP2024520395 A JP 2024520395A JP 2023572622 A JP2023572622 A JP 2023572622A JP 2023572622 A JP2023572622 A JP 2023572622A JP 2024520395 A JP2024520395 A JP 2024520395A
Authority
JP
Japan
Prior art keywords
formula
another embodiment
alkyl
alkylene
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023572622A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024520395A5 (cg-RX-API-DMAC7.html
Inventor
ヒューン,ホアン
ペニントン,ルイス,ディー.
チェ,ヨンギ
アクイラ,ブライアン,エム.
マッジ,インゴ,アンドレアス
フー,ユエン
ウッズ,ジェームズ,アール.
ライマー,ブライアン,ケネス
マーティン ベンツィエン,イョルグ
ウォード レーマン,ジョナサン
ヘール,マイケル,アール.
Original Assignee
アルカーメス,インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アルカーメス,インコーポレイテッド filed Critical アルカーメス,インコーポレイテッド
Publication of JP2024520395A publication Critical patent/JP2024520395A/ja
Publication of JP2024520395A5 publication Critical patent/JP2024520395A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2023572622A 2021-05-26 2022-05-25 置換される縮合二環式大環状化合物および関連のある治療方法 Pending JP2024520395A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163193243P 2021-05-26 2021-05-26
US63/193,243 2021-05-26
PCT/US2022/030839 WO2022251302A1 (en) 2021-05-26 2022-05-25 Substituted fused bicyclic macrocyclic compounds and related methods of treatment

Publications (2)

Publication Number Publication Date
JP2024520395A true JP2024520395A (ja) 2024-05-24
JP2024520395A5 JP2024520395A5 (cg-RX-API-DMAC7.html) 2024-12-27

Family

ID=82851881

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023572622A Pending JP2024520395A (ja) 2021-05-26 2022-05-25 置換される縮合二環式大環状化合物および関連のある治療方法

Country Status (7)

Country Link
US (1) US20240182491A1 (cg-RX-API-DMAC7.html)
EP (1) EP4347046A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024520395A (cg-RX-API-DMAC7.html)
CN (1) CN117999265A (cg-RX-API-DMAC7.html)
AU (1) AU2022281345A1 (cg-RX-API-DMAC7.html)
CA (1) CA3219506A1 (cg-RX-API-DMAC7.html)
WO (1) WO2022251302A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4680611A1 (en) 2023-03-16 2026-01-21 Takeda Pharmaceutical Company Limited Macrocyclic heterocycle compounds and use thereof
JP2026518313A (ja) 2023-06-01 2026-06-04 ハー・ルンドベック・アクチエゼルスカベット スピロ大環状オレキシン2受容体アゴニスト
CN122374291A (zh) 2023-12-12 2026-07-10 爱杜西亚药品有限公司 作为食欲素受体调节剂的芳基砜及砜酮衍生物
WO2025132542A1 (en) 2023-12-19 2025-06-26 Idorsia Pharmaceuticals Ltd Macrocyclic orexin agonists
WO2026017128A1 (zh) * 2024-07-17 2026-01-22 江苏恩华药业股份有限公司 作为食欲素受体激动剂的环烯烃衍生物及其组合物和用途
US20260109711A1 (en) * 2024-09-18 2026-04-23 Vertex Pharmaceuticals Incorporated Macrocyclic sulfonamide modulators
US20260144795A1 (en) 2024-11-27 2026-05-28 H. Lundbeck A/S Spiromacrocyclic orexin 2 receptor agonists

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019027003A1 (ja) * 2017-08-03 2019-02-07 武田薬品工業株式会社 複素環化合物およびその用途
JP2019504098A (ja) * 2016-02-04 2019-02-14 武田薬品工業株式会社 置換ピペリジン化合物およびその用途
WO2020004536A1 (ja) * 2018-06-29 2020-01-02 武田薬品工業株式会社 複素環化合物およびその用途
WO2020167706A1 (en) * 2019-02-13 2020-08-20 Merck Sharp & Dohme Corp. 5-alkyl pyrrolidine orexin receptor agonists

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8258163B2 (en) 2008-06-04 2012-09-04 Board Of Regents, The University Of Texas System Small-molecule agonists for type-2 orexin receptor
WO2014198880A1 (en) 2013-06-14 2014-12-18 Ferrer Internacional, S.A. 2-(2-aminophenoxy)-3-chloronaphthalene-1,4-dione compounds having orexin 2 receptor agonist activity
US20160250224A1 (en) 2013-09-24 2016-09-01 The Board Of Regents Of The University Of Texas System Orexin-control of bone formation and loss
WO2015073707A1 (en) 2013-11-15 2015-05-21 The Board Of Trustees Of The Leland Stanford Junior University Methods of treating heart failure with agonists of hypocretin receptor 2
SG11201604639YA (en) 2013-12-12 2016-07-28 Univ Tsukuba Sulfonamide derivative or pharmaceutically acceptable acid addition salt thereof
JP6552117B2 (ja) 2014-03-28 2019-07-31 国立大学法人 筑波大学 敗血症の予防治療剤
WO2018053302A1 (en) * 2016-09-19 2018-03-22 Ensemble Therapeutics Corporation Macrocyclic compounds for the inhibition of indoleamine-2,3-dioxygenase activity and use thereof
MA47233A (fr) * 2016-12-19 2019-10-23 Epizyme Inc Composés hétérocycliques substitués par une amine utilisés comme inhibiteurs de l'ehmt2 et leurs méthodes d'utilisation
US10428023B2 (en) 2017-08-03 2019-10-01 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
CN110156813B (zh) * 2018-02-13 2023-07-25 北京诺诚健华医药科技有限公司 作为trk抑制剂的杂环化合物
CN110627812B (zh) * 2018-06-25 2022-10-11 北京诺诚健华医药科技有限公司 作为trk抑制剂的杂环化合物
KR20260083444A (ko) * 2019-11-25 2026-06-05 알케르메스,인코포레이티드 치환된 마크로사이클릭 화합물 및 관련 치료 방법
EP4247801A4 (en) * 2020-11-23 2024-10-30 Merck Sharp & Dohme LLC 3-AMINO PYRROLIDINE AND MACROCYCLIC PIPERIDINE OREXIN RECEPTOR AGONISTS
US12006330B2 (en) * 2020-12-21 2024-06-11 Alkermes, Inc. Substituted macrocyclic compounds and related methods of treatment

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019504098A (ja) * 2016-02-04 2019-02-14 武田薬品工業株式会社 置換ピペリジン化合物およびその用途
WO2019027003A1 (ja) * 2017-08-03 2019-02-07 武田薬品工業株式会社 複素環化合物およびその用途
WO2020004536A1 (ja) * 2018-06-29 2020-01-02 武田薬品工業株式会社 複素環化合物およびその用途
WO2020167706A1 (en) * 2019-02-13 2020-08-20 Merck Sharp & Dohme Corp. 5-alkyl pyrrolidine orexin receptor agonists

Also Published As

Publication number Publication date
AU2022281345A1 (en) 2023-11-30
CA3219506A1 (en) 2022-12-01
US20240182491A1 (en) 2024-06-06
CN117999265A (zh) 2024-05-07
WO2022251302A1 (en) 2022-12-01
EP4347046A1 (en) 2024-04-10

Similar Documents

Publication Publication Date Title
JP7580136B2 (ja) Jak阻害剤化合物及びその使用
JP7862437B2 (ja) オレキシン-2受容体アゴニスト活性を有する置換されるアミド大環状化合物
CN116615427B (zh) 被取代的大环化合物及相关治疗方法
CN107074852B (zh) ROR-γ的二氢吡咯并吡啶抑制剂
JP7846113B2 (ja) 置換ピペリジノ化合物及び関連する治療方法
JP6517928B2 (ja) キナーゼ阻害剤として有用なインドールカルボキシアミド
CN104781254B (zh) 可作为激酶调节剂的经杂芳基取代的吡啶基化合物
CA3199074A1 (en) Compounds and methods for the targeted degradation of androgen receptor protein
WO2022251302A1 (en) Substituted fused bicyclic macrocyclic compounds and related methods of treatment
TW202134229A (zh) 環烷基尿素衍生物
JP2012504632A (ja) C型肝炎ウイルス阻害剤
WO2010058846A1 (ja) 4,6-ジアミノニコチンアミド化合物
WO2016039408A1 (ja) 複素環化合物
JP7833486B2 (ja) 置換されるカルバメート大環状化合物および関連のある治療方法
EP4543446A1 (en) Substituted fused bicyclic compounds and related methods of treatment
CN119730843A (zh) 取代的吡咯烷基和哌啶基化合物以及相关的治疗方法
JP2025521508A (ja) 置換ピロリジニル及びピペリジニル化合物並びに関連する治療方法
HK40106635A (en) Substituted carbamate macrocyclic compounds and related methods of treatment
HK40106635B (en) Substituted carbamate macrocyclic compounds and related methods of treatment
HK40108225A (en) Substituted amide macrocyclic compounds with orexin-2 receptor agonist activity
HK40108225B (en) Substituted amide macrocyclic compounds with orexin-2 receptor agonist activity
TW202542138A (zh) 與含patatin樣磷脂酶結構域蛋白3IM結合的化合物及其用於治療肝病之用途
JP2025521504A (ja) 置換縮合二環式化合物および関連する治療方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241219

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241219

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20251016

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251110

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260204

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260401

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260701

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260728